Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom